Gainers

• Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday's regular session. The market value of their outstanding shares is at $2.9 million.
• Cuprina Holdings (Cayman) (NASDAQ:CUPR) shares increased by 70.62% to $7.61. The market value of their outstanding shares is at $11.9 million.
• Abivax (NASDAQ:ABVX) stock moved upwards by 40.87% to $135.45. The company's market cap stands at $7.6 billion.
• C4 Therapeutics (NASDAQ:CCCC) stock moved upwards by 18.62% to $5.16. The company's market cap stands at $480.9 million.
• Bio Green Med Solution (NASDAQ:BGMS) stock rose 17.59% to $0.85. The company's market cap stands at $3.9 million.
• ProMIS Neurosciences (NASDAQ:PMN) shares moved upwards by 16.27% to $12.5. The market value of their outstanding shares is at $96.4 million.

Losers

• Vistagen Therapeutics (NASDAQ:VTGN) stock declined by 70.2% to $0.23 during Tuesday's regular session. The company's market cap stands at $31.1 million.
• Universe Pharmaceuticals (NASDAQ:UPC) shares declined by 52.39% to $5.8. The company's market cap stands at $7.8 million.
• Unicycive Therapeutics (NASDAQ:UNCY) stock declined by 40.91% to $4.55. The market value of their outstanding shares is at $210.9 million.
• Nuvectis Pharma (NASDAQ:NVCT) stock decreased by 35.86% to $18.3. The company's market cap stands at $756.7 million.
• Tenon Medical (NASDAQ:TNON) shares fell 27.31% to $0.32. The company's market cap stands at $5.2 million.
• Decoy Therapeutics (NASDAQ:DCOY) shares declined by 26.05% to $7.09. The market value of their outstanding shares is at $5.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.